Tiba Al Sagheer, PharmD, BCOP, BCACP

Presenters at the 2026 National ICE-T Conference in Orlando, Florida, discuss the efficacy and safety of novel agents across hematologic disease states.

Tiba Al Sagheer, PharmD, BCOP, BCACP, said CAR T-cell expansion signals toxicity risk differently across cilta-cel and ide-cel.

Differentiating between CRS and IEC-HS remains a challenge in mitigating toxicity associated with cellular therapy, said Tiba Al Sagheer, PharmD, BCOP, BCACP.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.